TAVOLARI, SIMONA
TAVOLARI, SIMONA
CENTRO INTERDIPARTIMENTALE ALMA MATER INSTITUTE ON HEALTHY PLANET
Assegnisti
Tavolari S.; Simona Tavolari; S. TAVOLARI
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies
2024 Brandi G.; Relli V.; Deserti M.; Palloni A.; Indio V.; Astolfi A.; Serravalle S.; Mattiaccio A.; Vasuri F.; Malvi D.; Deiana C.; Pantaleo M.A.; Cescon M.; Rizzo A.; Katoh M.; Tavolari S.
Intestinal Microbiota Increases Cell Proliferation of Colonic Mucosa in Human-Flora-Associated (HFA) Mice
2024 Brandi G.; Calabrese C.; Tavolari S.; Bridonneau C.; Raibaud P.; Liguori G.; Thomas M.; Di Battista M.; Gaboriau-Routhiau V.; Langella P.
Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue
2023 Brandi G.; Deiana C.; Galvani L.; Palloni A.; Ricci A.D.; Rizzo A.; Tavolari S.
Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study
2023 Vasuri, Francesco; Deserti, Marzia; Corradini, Angelo G; Tavolari, Simona; Relli, Valeria; Palloni, Andrea; Frega, Giorgio; Curti, Stefania; Mattioli, Stefano; Cescon, Matteo; D'Errico, Antonia; Brandi, Giovanni
Have We Found the “Holy Grail” That May Predict Response to Immunotherapy in Hepatocellular Carcinoma?
2023 Brandi G.; Tovoli F.; Tavolari S.
Mutational Landscape of Cholangiocarcinoma According to Different Etiologies: A Review
2023 Tavolari S.; Brandi G.
Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link
2022 Brandi, Giovanni; Straif, Kurt; Mandrioli, Daniele; Curti, Stefania; Mattioli, Stefano; Tavolari, Simona
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
2022 Di Federico A.; Mosca M.; Pagani R.; Carloni R.; Frega G.; De Giglio A.; Rizzo A.; Ricci D.; Tavolari S.; Di Marco M.; Palloni A.; Brandi G.
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
2022 Alessandro Di Federico, Mirta Mosca, Rachele Pagani, Riccardo Carloni, Giorgio Frega, Andrea De Giglio, Alessandro Rizzo, Dalia Ricci, Simona Tavolari, Mariacristina Di Marco, Andrea Palloni, Giovanni Brandi.
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience
2021 Rizzo, A.; Frega, G.; Palloni, A.; Piemontese, A.; Di Federico, A.; Ricci, A.; Carloni, R.; Fabbri, F.; Novelli, M.; Tavolari, S.; Di Marco, M.; Ravaioli, M.; Brandi, G.
Nivolumab: an investigational agent for the treatment of biliary tract cancer
2021 Di Federico A.; Rizzo A.; Ricci A.D.; Frega G.; Palloni A.; Tavolari S.; Brandi G.
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis
2020 Rizzo A.; Frega G.; Ricci A.D.; Palloni A.; Abbati F.; de Lorenzo S.; Deserti M.; Tavolari S.; Brandi G.
Asbestos and Intrahepatic Cholangiocarcinoma
2020 Brandi G.; Tavolari S.
Circulating tumor DNA in biliary tract cancer: Current evidence and future perspectives
2020 Rizzo A.; Ricci A.D.; Tavolari S.; Brandi G.
Current and novel therapeutic opportunities for systemic therapy in biliary cancer
2020 Marin J.J.G.; Prete M.G.; Lamarca A.; Tavolari S.; Landa-Magdalena A.; Brandi G.; Segatto O.; Vogel A.; Macias R.I.R.; Rodrigues P.M.; Casta A.L.; Mertens J.; Rodrigues C.M.P.; Fernandez-Barrena M.G.; Da Silva Ruivo A.; Marzioni M.; Mentrasti G.; Acedo P.; Munoz-Garrido P.; Cardinale V.; Banales J.M.; Valle J.W.; Bridgewater J.; Braconi C.
Evolution of the experimental models of cholangiocarcinoma
2020 Massa A.; Varamo C.; Vita F.; Tavolari S.; Peraldo-Neia C.; Brandi G.; Rizzo A.; Cavalloni G.; Aglietta M.
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis
2020 Rizzo A.; Ricci A.D.; Frega G.; Palloni A.; De Lorenzo S.; Abbati F.; Mollica V.; Tavolari S.; Di Marco M.; Brandi G.
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS
2020 G Brandi, M Deserti, A Palloni, D Turchetti, R Zuntini, F Pedica, G Frega, S De Lorenzo, F Abbati, A Rizzo, M Di Marco, F Massari, S Tavolari
Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases?
2020 Brandi G.; Ricci A.D.; Rizzo A.; Zanfi C.; Tavolari S.; Palloni A.; De Lorenzo S.; Ravaioli M.; Cescon M.
Molecular features and targeted therapies in extrahepatic cholangiocarcinoma: Promises and failures
2020 Rizzo A.; Tavolari S.; Ricci A.D.; Frega G.; Palloni A.; Relli V.; Salati M.; Fenocchio E.; Massa A.; Aglietta M.; Brandi G.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies | Brandi G.; Relli V.; Deserti M.; Palloni A.; Indio V.; Astolfi A.; Serravalle S.; Mattiaccio A.; ...Vasuri F.; Malvi D.; Deiana C.; Pantaleo M.A.; Cescon M.; Rizzo A.; Katoh M.; Tavolari S. | 2024-01-01 | SCIENTIFIC REPORTS | - | 1.01 Articolo in rivista | Brandi_2024.pdf; 41598_2024_52991_MOESM8_ESM.zip |
| Intestinal Microbiota Increases Cell Proliferation of Colonic Mucosa in Human-Flora-Associated (HFA) Mice | Brandi G.; Calabrese C.; Tavolari S.; Bridonneau C.; Raibaud P.; Liguori G.; Thomas M.; Di Battis...ta M.; Gaboriau-Routhiau V.; Langella P. | 2024-01-01 | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - | 1.01 Articolo in rivista | - |
| Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue | Brandi G.; Deiana C.; Galvani L.; Palloni A.; Ricci A.D.; Rizzo A.; Tavolari S. | 2023-01-01 | FRONTIERS IN ONCOLOGY | - | 1.01 Articolo in rivista | Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma.pdf |
| Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study | Vasuri, Francesco; Deserti, Marzia; Corradini, Angelo G; Tavolari, Simona; Relli, Valeria; Pallon...i, Andrea; Frega, Giorgio; Curti, Stefania; Mattioli, Stefano; Cescon, Matteo; D'Errico, Antonia; Brandi, Giovanni | 2023-01-01 | SCIENTIFIC REPORTS | - | 1.01 Articolo in rivista | 70-Vasuri et al_Sci Rep 2023.pdf; 41598_2023_27791_MOESM1_ESM.pdf |
| Have We Found the “Holy Grail” That May Predict Response to Immunotherapy in Hepatocellular Carcinoma? | Brandi G.; Tovoli F.; Tavolari S. | 2023-01-01 | GASTROENTEROLOGY | - | 1.01 Articolo in rivista | - |
| Mutational Landscape of Cholangiocarcinoma According to Different Etiologies: A Review | Tavolari S.; Brandi G. | 2023-01-01 | CELLS | - | 1.01 Articolo in rivista | Mutational Landscape of Cholangiocarcinoma According to.pdf |
| Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link | Brandi, Giovanni; Straif, Kurt; Mandrioli, Daniele; Curti, Stefania; Mattioli, Stefano; Tavolari,... Simona | 2022-01-01 | ANNALS OF GLOBAL HEALTH | - | 1.01 Articolo in rivista | 66-Brandi et al_Ann Glo Health 2022.pdf |
| Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes | Di Federico A.; Mosca M.; Pagani R.; Carloni R.; Frega G.; De Giglio A.; Rizzo A.; Ricci D.; Tavo...lari S.; Di Marco M.; Palloni A.; Brandi G. | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | articolo 2022 Immunotherapy in Pancreatic Cancer Why Do We Keep Failing A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes.pdf |
| Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes | Alessandro Di Federico, Mirta Mosca, Rachele Pagani, Riccardo Carloni, Giorgio Frega, Andrea De G...iglio, Alessandro Rizzo, Dalia Ricci, Simona Tavolari, Mariacristina Di Marco, Andrea Palloni, Giovanni Brandi. | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-14-02429 (1).pdf |
| Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience | Rizzo, A.; Frega, G.; Palloni, A.; Piemontese, A.; Di Federico, A.; Ricci, A.; Carloni, R.; Fabbr...i, F.; Novelli, M.; Tavolari, S.; Di Marco, M.; Ravaioli, M.; Brandi, G. | 2021-01-01 | ANNALS OF ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Nivolumab: an investigational agent for the treatment of biliary tract cancer | Di Federico A.; Rizzo A.; Ricci A.D.; Frega G.; Palloni A.; Tavolari S.; Brandi G. | 2021-01-01 | EXPERT OPINION ON INVESTIGATIONAL DRUGS | - | 1.01 Articolo in rivista | - |
| Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis | Rizzo A.; Frega G.; Ricci A.D.; Palloni A.; Abbati F.; de Lorenzo S.; Deserti M.; Tavolari S.; Br...andi G. | 2020-01-01 | IN VIVO | - | 1.01 Articolo in rivista | - |
| Asbestos and Intrahepatic Cholangiocarcinoma | Brandi G.; Tavolari S. | 2020-01-01 | CELLS | - | 1.01 Articolo in rivista | Asbestos and Intrahepatic Cholangiocarcinoma.pdf |
| Circulating tumor DNA in biliary tract cancer: Current evidence and future perspectives | Rizzo A.; Ricci A.D.; Tavolari S.; Brandi G. | 2020-01-01 | CANCER GENOMICS & PROTEOMICS. | - | 1.01 Articolo in rivista | - |
| Current and novel therapeutic opportunities for systemic therapy in biliary cancer | Marin J.J.G.; Prete M.G.; Lamarca A.; Tavolari S.; Landa-Magdalena A.; Brandi G.; Segatto O.; Vog...el A.; Macias R.I.R.; Rodrigues P.M.; Casta A.L.; Mertens J.; Rodrigues C.M.P.; Fernandez-Barrena M.G.; Da Silva Ruivo A.; Marzioni M.; Mentrasti G.; Acedo P.; Munoz-Garrido P.; Cardinale V.; Banales J.M.; Valle J.W.; Bridgewater J.; Braconi C. | 2020-01-01 | BRITISH JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
| Evolution of the experimental models of cholangiocarcinoma | Massa A.; Varamo C.; Vita F.; Tavolari S.; Peraldo-Neia C.; Brandi G.; Rizzo A.; Cavalloni G.; Ag...lietta M. | 2020-01-01 | CANCERS | - | 1.01 Articolo in rivista | Evolution of the Experimental Models.pdf |
| How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis | Rizzo A.; Ricci A.D.; Frega G.; Palloni A.; De Lorenzo S.; Abbati F.; Mollica V.; Tavolari S.; Di... Marco M.; Brandi G. | 2020-01-01 | IN VIVO | - | 1.01 Articolo in rivista | - |
| INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS | G Brandi, M Deserti, A Palloni, D Turchetti, R Zuntini, F Pedica, G Frega, S De Lorenzo, F Abbati..., A Rizzo, M Di Marco, F Massari, S Tavolari | 2020-01-01 | CANCER GENETICS | - | 1.01 Articolo in rivista | Articolo di marco 2020 Cancer Genetics.pdf; 1-s2.0-S2210776220302763-mmc1.docx |
| Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases? | Brandi G.; Ricci A.D.; Rizzo A.; Zanfi C.; Tavolari S.; Palloni A.; De Lorenzo S.; Ravaioli M.; C...escon M. | 2020-01-01 | CANCER COMMUNICATIONS | - | 1.01 Articolo in rivista | cac2.12072.pdf |
| Molecular features and targeted therapies in extrahepatic cholangiocarcinoma: Promises and failures | Rizzo A.; Tavolari S.; Ricci A.D.; Frega G.; Palloni A.; Relli V.; Salati M.; Fenocchio E.; Massa... A.; Aglietta M.; Brandi G. | 2020-01-01 | CANCERS | - | 1.01 Articolo in rivista | Molecular Features and Targeted Therapies in.pdf |